预约演示
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
2023-12-02
临床结果
Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from pediatric to long-term adult care2
These research and findings demonstrate UCB's commitment to symptom management as well as holistic patient care
ATLANTA, Dec. 2, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced data being presented at the American Epilepsy Society (AES) Annual Meeting, taking place December 1–5 in Orlando, Florida, that focus on the real-world experiences of people living with rare epilepsy syndromes and their caregivers, in addition to several other presentations of clinical data evaluating the efficacy, safety and tolerability of FINTEPLA as a treatment for seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Continue Reading
Fintepla® (fenfluramine) 2.2 mg/mL oral solution)
Finteplaivifenfluraminevere group of rare epilepsies called developmental and epileptic encephalopathies (DEEs), including DS and LGS, experience frequent and prolonged seizures, significant behavioral and developmental delays, movement and balance issues, and sleep difficulties.4 These ongoing challenges can create significant obstacles for both patients and their caregivers, as the conditions often require consistent and lifelong management to mitigate the dangerous side effects and detrimental impacts on quality of life.5
"It is critical to address not only seizurepilepsieso the nodevelopmental and epileptic encephalopathies (DEEs) quality of life foLGSeople living with rare epilepsies anseizurescaregivers," said Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes at UCB. "The robust data being presented at AES reflect UCB's commitment to research and resources that support the rare epilepsy community. By continuing to deepen our understanding of the real-world experiences faced by people living with rare epilepsy syndromes (acute repetitive seizures and focal epilepsy), we will be able to better support their journey to finding appropriate treatment options faster and provide resources and education over the long term."
The real-world evidence being presenseizuresES supports the neseizurentegrate the lived experiences of the rare epilepsy community into the development of tepilepsiesptions and resources, to bring more holistic care to peoEpilepsyng with rare epilepsiesUCBd their caregivers.UCBepilepsyepilepsyacute repetitive seizuresfocal epilepsy
"Providing proactive education and counseling for people living with rare epilepsy syndromes and their caregiverepilepsytical for improving seizure control, appropriate treatment adherence and management of risks like SUDEP," said Tom Starare epilepsies of the Danny Did Foundation and study investigator. "To achieve effective communication, neurologists need support to help them initiate difficult discussions about potentially negative impacts on quality of life. With the proper tools, providers can play a big role to empower and inform patients and caregivers."
A 12-Month Persistence fenfluramineFenfluramine, Valproate, and Levetiepilepsy syndromeduals with DravSUDEPndrome: A Comparison Using U.S. Claims Data1
A new analysis utilizing U.S. real-Fenfluraminef Valproateine inLevetiracetamg with DS.1Dravet Syndrome
Data from this late-breaking poster presentation fenfluramine. healthcare claims data from Komodo Healthcare showing the persistency of fenfluramine – defined as the duration of continuous treatment without a gap of more than 90 days.1
A Survey of Rare Epilepsy Parents and Adult Siblings: To Assess Resources Needed to PrepareKomodo Healthcarein the U.S. for Long-term Adfenfluraminenning for Their Loved One2
Survey assessed rEpilepsy and needs required for caregivers' long-term care planning for a family member diagnosed with a developmental and epileptic encephalopathy (DEE). 2
Data from a survey of 135 caregivers of people with rare epilepsy syndromes, including parents and adult siblings, found tdevelopmental and epileptic encephalopathy (DEE)o long-term care planning information, while 53% did not have information available to them, and 24% were unsure. Those surveyed cited frustration in finding support and resources for patients with rare epilepsy syndromes and concern about how patients and their caregivers will be supported as they transition into adulthood.2
No family support programs or resources currently exist fepilepsyterm adult care planning or for the transfer of primary care for those living with rare epilepsy syndromes, uncovering a significant unmet need for additional support to facilitate future medical, legal and financial planning and ensure caregivers have access to resources and support at every step of their epilepsyrney.2
Bridging The Gap Between Neurologists and People with Epilepsy/Caregivers: Systematic Literature Repilepsy
eview about SUDEP Conversations3Epilepsy
Research looks to understand and learn more about caregivers' needs and experiences and neurologists' attitudes and behaviors toward SUDEP conversations. 3
A critical element of care for people living with epilepsy and rare epilepsy syndromes is the continuous management of risk related to sudden unexpected death in epilepsy (SUDEP), a leading disease-related cause of mortality among people living with epilepsy, affecting approximately one in 1,000 adults with epilepsy yearly6 and one in 150 for those with inadequate seizure control.7 A systematic literature review of studies found a gap between what people living with epilepsy and their caregivers want regarding information about SUDEP and the information shared with them by their neurologists.3
While many neurologists reported not actively discepilepsyUDEP to avepilepsying fear or negative emotions, data show that patients and caregivers want to have morepilepsyive discussions about SUDEP to provide them with the opportunity to take preventepilepsyures. Increasing education for people with epilepsyepilepsyir caregivers about SUDEP, as well as providing neurologists with support and training to become adept at initiating these difficult discussions, are critepilepsyhelp build a trusting partnership to enhance epilepsy mSUDEPment and, in turn, reduce the risks of SUDEP.3
EpilepEpilepsycommon neurological condition worldwide and affects approximately 50 million people.8 Epilepsy and seizures can develop in any person at any age9 and is usually diagnosed after a person has had at least two seizures (or after one seizure with a high risk for more) that were not caused by some known medical condition.10
For thUCB decEpilepsy've been committed to people living with epilepsy and their families, surrounding the patient and caregiver through every step of their care journey. At our core, we have a responsibility to elevate the healthcare ecosystem. Because of this, we have established our legitimacy on the front lines of epilepsy research, development, and treatment innovation. But our past breakthroughs are only a prologue to our future. We will continue to reimagine how we care for patients, leveraging today's expertise for a better tomorrow. With so much experience behind us and so much potential ahead,
About FINTEPLA® (fenfluramine)epilepsyepilepsy syndrome
Oral SFINTEPLAfenfluramine
11
FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
FINTEPLA is available only through a restriseizurestribution programDravet syndrome (DS) REMSLennox-Gastaut syndrome (LGS)lable at www.FINTEPLAREMS.com or by telephone at +1 877 964 3649.
FINTEPLAT SAFETY INFORMATION
BOXED WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION
There is an assVALVULAR HEART DISEASEonergPULMONARY ARTERIAL HYPERTENSIONgonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hypertension.
Echocardiogram assessments are required before, during, 5-HT2B receptor agonist5-HT2B receptorment with FINTEPLA.fenfluramineFINTEPLAvalvular heart diseasepulmonary arterial hypertension
FINTEPLA is available only through a restricted program called the FINTEPLA REMS.FINTEPLA
FINTEPLADICATIONS
FINTEPLA is contraindicated in patients with hypersensitivity to fenfluramine or any of the excipients in FINTEPLA and with concomitant use, or within 14 days of the administration, of monoamine oxidase inhibitors because of an increased risk of serotonin syndrome.
Valvular Heart Disease and Pulmonary Arterial Hypertension (see Boxed Warning): Because of the association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease (VHD) and pulmonary arterial hypertension (PAH), cardiac monitoring via echocardiogram is required prior to starting treatment, during treatment, and after treatment with FINTEPLA concludes. Cardiac monitoring via echocardiogram can aid in early detection of these conditions. In clinical trials for DS and LGS of up to 3 years in duration, no patient receiving FINTEPLA developed VHD or PAH.
Valvular Heart DiseasetartiPulmonary Arterial Hypertensionergo an echocardiogram to evaluate for VHD and PAH. Echocardiograms should be rep5-HT2B receptor agonist5-HT2B receptoronths, and once at 3-6 monthsfenfluramineent with FINTEPLA.FINTEPLAvalvular heart disease (VHD)pulmonary arterial hypertension (PAH)FINTEPLAFINTEPLAPAH
The prescriber must consider the benefits versus the risks of initiating or continuing treatment with FINPAHLA if any of the following signs are observed via echocardiogram: valvular abnormality or new abFINTEPLAy; VHD indicated by mild or greater aortic regurgitation or moderate or greater mitral regurgitation, with additional characteristics of VHD (eg, valve thickening or restrictive valve motion); PAH indicated by elevated right heart/pulmonary artery pressure (PASP >35 mmHg).
FINTEPLA REMS Program (see Boxed Warning): FINTEPLA is available only through a restricted distributioFINTEPLAm called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribers must be certified by enrolling in the FINTEPLA Raortic regurgitationt counsel patients receimitral regurgitationthe risk of VHD and PAH, how to recognize signs and symptoms of VHD and PAH, the need for basPAHne (pretreatment) and periodic cardiac monitoring via echocardiogram during FINTEPLA treatment, and cardiac monitoring after FINTEPLA treatment. Patients must enroll in the FINTEPLA REMS and comply with ongoing monitoring requirements. The pharmacy must be certified by enrolling in the FINTEPLA REMS and must only dispense to patients who are authorized to receive FINTEPLA. Wholesalers and distributors must only distribute to certified pharmacies. Further information is available at www.FINTEPLAREMS.com or by telephone at 1-877-964-3649.
Decreased Appetite and Decreased Weight: FIFINTEPLAan cause decreases in appetite and weight. Decreases in weight appear to be dose related. Approximately half of the patients with LGS and most patients with DS resumed the expected measured increases in weight during the open-label extension studFINTEPLAght should be monitored regPAHrly during treatment with FINTEPLA, and dose modiPAHations should be considered if a decrease in weight is observed.FINTEPLAFINTEPLAFINTEPLAFINTEPLA
Somnolence, Sedation, and Lethargy: FINTEFINTEPLAcause somnolence, sedation, and lethargy. Other central nervous system (CNS) depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient FINTEPLAce on FINTEPLA to gauge whether it adversely affects their ability to drive or operate machinery.
Suicidal BehSedationd IdeaLethargytiepileptic drugs (AEsomnolencedisedationPLA, ilethargythe risk of suicidal thoughts or behaviors in patients takinalcohol drugs for any indication. Patients FINTEPLAwith an AED for any indication should be msomnolenceor thsedationnce or worsening of depression, suicidal thoughts or behaviors, or any unusual changes in mood or behavior.FINTEPLA
Anyone considering prescribing FINTEPLA or any other AED must balance FINTEPLA of suicidal thoughts or behaviors with the risks of untreated illness. Epilepsy and many other illnesses for which AEDs are prescAEDed are themselves associated with morbidity and mortality and an increaseddepressionuicidal thoughts and behaviors. Should suicidal thoughts and behaviors emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
Serotonin Syndrome: Serotonin syndrome, a potentially FINTEPLAeatening condition, may occur with FINTEPLA, particularly during concomitaseizurenistration of Fstatus epilepticus serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, dietary supplements (eg, St. John's Wort, tryptophan), drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs], which are contraindicated with FINTEPLA), dextromethorphan, lithium, tramadol, and antipsychotics with serotonergic agonist activity. Patients should be monitored for the emergence of signs and symptoms of serotonin syndrome, which include mental status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (eg, hyperreflexia, incoordination), and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). If serotonin syndrome is suspected, treatment with FINTEPLA should be stopped immediately and symptomatic treatment should be started.
Serotonin SyndromePrSerotonin syndromean cause an increase in blood pressure. Rare cases of signiFINTEPLAlevation in blood pressure, including hypertensive cFINTEPLAas been reported in adult patients treated with fenfluramine, including patients without a history of hypertension. In clinical trials for DS and LGS of up to 3 years in duration, no pediatric or adult patient bupropion FINTEPLA developed hypertensive crisis. Monitor blood pressure in patients treated with FINTEPLA.monoamine oxidase inhibitorsFINTEPLAdextromethorphanserotonin syndromeagitationhallucinationscomatachycardiahyperthermiaincoordinationnauseavomitingdiarrheaserotonin syndromeFINTEPLA
Glaucoma: Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma. Consider discontinuing treatment with FINTEPLA in patients with acute decreases in visual acuity or ocular pain.fenfluraminehypertensionLGSFINTEPLAFINTEPLA
The most common adverse reactions observed in DS studies (incidence at least 10% and greater than placebo) were decreased appetite; somnolence, sedation, lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue, malaise, asthenia; ataxia, balance disorder, gait disturbance; blood pressure increased; drooling, salivary hypersecretion; pyrexia; upper respiratory tract infection; vomiting; decreased weight; fall; status epilepticus.
The most common adverse reactions observed in the LGS study (incidence at least 10% and greater than placebo) wedecreased appetiteassomnolencee;sedation; lethargycediarrheangconstipationfatigueastheniaataxiabalance disordergait disturbancedroolingsalivary hypersecretionpyrexiaupper respiratory tract infectionvomitingstatus epilepticus
DRUG INTERACTIONSdiarrheadecreased appetitefatiguesomnolencevomiting
Strong CYP1A2, CYP2B6, or CYP3A Inducers: Coadministration with strong CYP1A2, CYP2B6, or CYP3A inducers will decrease fenfluramine plasma concentrations. If coadministration of a strong CYP1A2, CYP2B6, or CYP3A inducer with FINTEPLA is necessary, monitor the patient for reduced efficacy and consider increasing the dosage of FINTEPLA as needed. If a strong CYP1A2, CYP2B6, or CYP3A inducer is discontinued during maintenance treatment with FINTEPLA, consider gradual reduction in the FINTEPLA dosage to the dose administered prior to initiating the inducer.
Strong CYP1A2 oCYP2B6D6 InCYP3Aors: Coadministration with strong CYP1A2CYP1A2P2CYP2B6ibitors will increase fenfluraminefenfluramineentrations. If FINTEPLA is coadministered with strong CYCYP1A2r CYP2B6 inhibitors, the maximumFINTEPLAosage of FINTEPLA is 20 mg. If a strong CYP1A2 or CYP2D6 inhibitor is discontinued during mainFINTEPLAtreatment with FINTEPLA,CYP1A2deCYP2B6ual iCYP3Asinducere FINTEPLA dosage to the dose recommended without CFINTEPLA CYP2D6 inhibitors. If FINTEPLA is cFINTEPLAtered with stiripentol and a strong CYP1A2 or CYP2D6 inhibitor, the maximum daily dosage of FINTEPLA is 17 mg.
In patients with severe impairment of kidney function (estimated glomerular filtration rate [eGFR]) 15 to 29 mL/min/1.73m2, dosage adjustments are recommended. FINTEPLA has not been studied in patients with kidney failure (eGFR 1.73m2).
Combined molar exposures of fenfluramine and norfenfluramine were increased in subjects with various degrees of hepatic impairment (Child-Pugh Class A, B, and CFINTEPLAsitating a dosage adjustment in these pkidney failure
To report SUSPECTED ADVERSE fenfluramineontact UCB, Inc. at 1‑844-599-2273 or FDA at 1-800-FDA-1088 orhepatic impairment
www.fda.gov/medwatchUCB, Inc.
.
Please see full
Prescribing Information
, including Boxed Warning and
Medication Guide
, for additional Important Safety Information on FINTEPLA.
For further information, contact UCB:FINTEPLA
Corporate CommunicationsUCB
Becky Malone, U.S. Media Relations
T +919.605.9600
[email protected]
Investor Relations
Antje Witte
T +32.2.559.9414
[email protected]
About UCB
UCB, BUCBsels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,600 people in approximately 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA.
Jaganathan S, et al. A 12-month persistence analysis of fenfluramine, valproate, and levetiracetam in individuals with Dravet Syndrome: a comparison using US claims data. Poster presented at American Epilepsy Society Annual Meeting; December 1-5, 2023; Orlando, Florida.
Laurie D Bailey, et al. A Survey of Rare Epilepsy ParentfenfluramineSivalproateo AsselevetiracetamNeeded to Prepare FamDravet Syndrome the U.S. for Long-term Adult Care Planning for Their Loved. AbstrEpilepsyented at American Epilepsy Society Annual Meeting; December 1-5, 2023; Orlando, Florida.
Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rateDravet SyndromeorEpilepsyt of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017;88:1674-1680.
Meyer AC, Dua T, Ma J, et al. Global disparities in the epilepsy treatment gap: a systemic review. Bull World Health Organ. 2010;88: 260-266.
Epilepsy Foundation. Who Can Get Epilepsy? Available at:epilepsy/www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy. Accessed November 2023.
Epilepsy Foundation: What is EpilEpilepsyailable at: httphttps://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy23.
Epilepsy Foundationine) oral Epilepsy: U.S. prescribihttps://www.epilepsy.com/learn/about-epilepsy-basics
FINTEPLA® fenfluraminered trademark of the UCB Group of Companies.UCB, Inc.
FINTEPLAB, Inc., Smyrna, GA 30080. All righUCB Group of Companies0166
SOURCEUCB, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。